Skip to main content
. 2022 Jan 31;29(2):741–757. doi: 10.3390/curroncol29020063

Figure 3.

Figure 3

Study design of the PORTEC-4a trial. Reprinted with permission from “PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer [52]. HIR high intermediate risk, EBRT external beam radiation therapy, POLE polymerase epsilon, MMRd mismatch repair deficiency, LVSI lymphovascular space invasion, L1CAM L1 cell adhesion molecule, CTNNB1 beta catenin 1. (A) Study design of the PORTEC-4a trial. (B) Decision tree of the molecular-integrated risk profile.